EPS for BioPharmX (BPMX) Expected At $-0.06; Martingale Asset Management LP Has Lifted Voya Finl (VOYA) Stake By $511,344

December 1, 2017 - By Henry Gaston

Analysts expect BioPharmX Corporation (NYSEAMERICAN:BPMX) to report $-0.06 EPS on December, 12.They anticipate $0.07 EPS change or 53.85% from last quarter’s $-0.13 EPS. After having $-0.06 EPS previously,

BioPharmX Corporation’s analysts see 0.00% EPS growth. It closed at $0.125 lastly. It is up 5.75% since December 1, 2016 and is downtrending. It has underperformed by 22.45% the S&P500.

Martingale Asset Management LP increased Voya Finl Inc (VOYA) stake by 22.37% reported in 2017Q2 SEC filing. Martingale Asset Management LP acquired 14,204 shares as Voya Finl Inc (VOYA)’s stock declined 15.66%. The Martingale Asset Management LP holds 77,690 shares with $2.87M value, up from 63,486 last quarter. Voya Finl Inc now has $7.95 billion valuation. The stock increased 0.61% or $0.27 during the last trading session, reaching $44.2. About 1.72M shares traded or 27.42% up from the average. Voya Financial, Inc. (NYSE:VOYA) has risen 11.06% since December 1, 2016 and is uptrending. It has underperformed by 5.64% the S&P500.

Among 14 analysts covering Voya Financial (NYSE:VOYA), 11 have Buy rating, 1 Sell and 2 Hold. Therefore 79% are positive. Voya Financial had 32 analyst reports since August 26, 2015 according to SRatingsIntel. Morgan Stanley upgraded Voya Financial, Inc. (NYSE:VOYA) on Wednesday, November 11 to “Overweight” rating. On Tuesday, April 11 the stock rating was maintained by Wood with “Buy”. JP Morgan downgraded the shares of VOYA in report on Tuesday, January 3 to “Underweight” rating. The firm has “Buy” rating given on Wednesday, November 1 by RBC Capital Markets. The firm has “Buy” rating by Citigroup given on Thursday, January 26. On Monday, July 10 the stock rating was maintained by RBC Capital Markets with “Buy”. On Thursday, February 11 the stock rating was upgraded by JP Morgan to “Neutral”. On Monday, November 13 the stock rating was upgraded by Sandler O’Neill to “Buy”. On Monday, January 9 the stock rating was upgraded by Wells Fargo to “Outperform”. The firm earned “Buy” rating on Tuesday, July 25 by Keefe Bruyette & Woods.

Investors sentiment decreased to 0.72 in Q2 2017. Its down 0.23, from 0.95 in 2017Q1. It dropped, as 48 investors sold VOYA shares while 121 reduced holdings. 34 funds opened positions while 88 raised stakes. 170.81 million shares or 3.71% less from 177.38 million shares in 2017Q1 were reported. Nomura Incorporated has invested 0% of its portfolio in Voya Financial, Inc. (NYSE:VOYA). Aviva Public Ltd Liability Com accumulated 0.02% or 119,616 shares. Moreover, Riverhead Capital Management Llc has 0.01% invested in Voya Financial, Inc. (NYSE:VOYA) for 2,920 shares. Guggenheim Cap Ltd Company invested in 0% or 43,080 shares. Stevens Cap Management Ltd Partnership holds 0.05% or 38,493 shares in its portfolio. Penn Cap Management accumulated 119,607 shares or 0.34% of the stock. Tillar invested in 2.34% or 81,505 shares. Parametric Assoc Limited Liability Com owns 1.69M shares or 0.08% of their US portfolio. Artemis Inv Management Llp invested 0.06% in Voya Financial, Inc. (NYSE:VOYA). Focused Wealth Mngmt accumulated 5,200 shares or 0.07% of the stock. Stifel reported 0.01% in Voya Financial, Inc. (NYSE:VOYA). Citadel Advisors Limited Liability Company has 0% invested in Voya Financial, Inc. (NYSE:VOYA). Barclays Public Limited Company accumulated 85,265 shares. Ny State Teachers Retirement holds 0% of its portfolio in Voya Financial, Inc. (NYSE:VOYA) for 16,800 shares. Metropolitan Life Ins Ny holds 0% or 5,551 shares in its portfolio.

Martingale Asset Management LP decreased Bard (C R) (NYSE:BCR) stake by 21,810 shares to 104,632 valued at $33.08M in 2017Q2. It also reduced Summit Hotel Properties (NYSE:INN) stake by 24,209 shares and now owns 330,106 shares. Amgen Inc (NASDAQ:AMGN) was reduced too.

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter products that address dermatology and womenÂ’s health markets. The company has market cap of $15.62 million. The firm offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). It currently has negative earnings. The Company’s clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris.


Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.